Haisco Pharmaceutical Group Co., Ltd.
SZSE:002653.SZ
23.19 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 3,304.526 | 3,015.294 | 2,773.315 | 3,329.6 | 3,937.34 | 3,426.664 | 1,856.161 | 1,435.607 | 1,212.453 | 1,210.595 | 992.337 | 802.069 | 604.43 | 581.585 | 484.571 | 358.762 |
Cost of Revenue
| 1,028.047 | 919.277 | 943.424 | 1,063.232 | 1,348.242 | 1,489.156 | 657.786 | 370.876 | 399.415 | 366.45 | 268.699 | 204.311 | 200.946 | 199.697 | 140.872 | 109.488 |
Gross Profit
| 2,276.479 | 2,096.018 | 1,829.891 | 2,266.368 | 2,589.099 | 1,937.508 | 1,198.375 | 1,064.731 | 813.038 | 844.145 | 723.638 | 597.759 | 403.484 | 381.888 | 343.7 | 249.275 |
Gross Profit Ratio
| 0.689 | 0.695 | 0.66 | 0.681 | 0.658 | 0.565 | 0.646 | 0.742 | 0.671 | 0.697 | 0.729 | 0.745 | 0.668 | 0.657 | 0.709 | 0.695 |
Reseach & Development Expenses
| 501.378 | 447.866 | 434.13 | 405.532 | 235.422 | 204.224 | 119.198 | 115.004 | 157.492 | 126.143 | 59.701 | 62.85 | 32.177 | 23.95 | 18.873 | 8.264 |
General & Administrative Expenses
| 112.303 | 76.119 | 86.069 | 78.039 | 59.522 | 48.586 | 65.92 | 52.845 | 38.231 | 24.263 | 26.278 | 33.352 | 20.792 | 14.615 | 12.329 | 5.886 |
Selling & Marketing Expenses
| 1,200.383 | 1,136.158 | 976.331 | 1,269.516 | 1,713.407 | 1,327.459 | 754.375 | 479.372 | 178.183 | 215.536 | 144.402 | 127.785 | 26.681 | 20.49 | 19.231 | 11.739 |
SG&A
| 1,481.792 | 1,212.278 | 1,062.399 | 1,347.555 | 1,772.929 | 1,376.046 | 820.295 | 532.217 | 216.414 | 239.799 | 170.679 | 161.136 | 47.473 | 35.105 | 31.56 | 17.626 |
Other Expenses
| 13.398 | 251.123 | 215.117 | 62.189 | 30.532 | -0.931 | -7.176 | 152.889 | 10.901 | 50.203 | 110.467 | 135.018 | 83.066 | 73.665 | 47.666 | 10.042 |
Operating Expenses
| 1,969.772 | 1,911.267 | 1,711.646 | 1,815.277 | 2,038.883 | 1,593.864 | 975.01 | 774.862 | 472.616 | 455.653 | 306.555 | 276.65 | 122.038 | 93.358 | 77.255 | 38.372 |
Operating Income
| 306.707 | 364.444 | 512.257 | 698.798 | 546.795 | 323.963 | 265.961 | 347.886 | 405.081 | 454.518 | 461.296 | 348.812 | 287.362 | 290.691 | 269.359 | 207.344 |
Operating Income Ratio
| 0.093 | 0.121 | 0.185 | 0.21 | 0.139 | 0.095 | 0.143 | 0.242 | 0.334 | 0.375 | 0.465 | 0.435 | 0.475 | 0.5 | 0.556 | 0.578 |
Total Other Income Expenses Net
| 59.465 | 2.17 | -1.516 | -9.346 | -0.38 | -20.611 | 35.42 | 210.208 | 74.798 | 116.056 | 151.754 | 159.223 | 87.942 | 75.339 | 49.157 | 6.237 |
Income Before Tax
| 366.171 | 366.614 | 510.741 | 689.452 | 546.415 | 323.032 | 258.785 | 500.076 | 415.22 | 504.547 | 568.838 | 480.332 | 369.388 | 363.869 | 315.602 | 217.14 |
Income Before Tax Ratio
| 0.111 | 0.122 | 0.184 | 0.207 | 0.139 | 0.094 | 0.139 | 0.348 | 0.342 | 0.417 | 0.573 | 0.599 | 0.611 | 0.626 | 0.651 | 0.605 |
Income Tax Expense
| 6.96 | -25.03 | -6.841 | 88.247 | 71.565 | 5.491 | 29.681 | 47.429 | 43.062 | 54.006 | 49.619 | 37.271 | 57.092 | 58.116 | 31.883 | 22.053 |
Net Income
| 295.112 | 391.644 | 517.582 | 636.621 | 493.892 | 333.229 | 237.553 | 452.724 | 372.158 | 450.541 | 519.219 | 443.061 | 312.296 | 305.753 | 283.719 | 195.087 |
Net Income Ratio
| 0.089 | 0.13 | 0.187 | 0.191 | 0.125 | 0.097 | 0.128 | 0.315 | 0.307 | 0.372 | 0.523 | 0.552 | 0.517 | 0.526 | 0.586 | 0.544 |
EPS
| 0.26 | 0.36 | 0.48 | 0.6 | 0.46 | 0.31 | 0.22 | 0.41 | 0.35 | 0.42 | 0.48 | 0.41 | 0.32 | 0.32 | 0.31 | 0.21 |
EPS Diluted
| 0.26 | 0.36 | 0.48 | 0.6 | 0.46 | 0.31 | 0.22 | 0.41 | 0.35 | 0.42 | 0.48 | 0.41 | 0.32 | 0.32 | 0.31 | 0.21 |
EBITDA
| 529.2 | 606.544 | 694.474 | 841.262 | 664.915 | 446.279 | 344.169 | 593.795 | 485.507 | 560.444 | 601.948 | 505.92 | 389.689 | 374.408 | 323.574 | 226.409 |
EBITDA Ratio
| 0.16 | 0.201 | 0.25 | 0.253 | 0.169 | 0.13 | 0.185 | 0.414 | 0.4 | 0.463 | 0.607 | 0.631 | 0.645 | 0.644 | 0.668 | 0.631 |